about
Hypersensitivity to chemoradiation in FANCA carrier with cervical carcinoma-A case report and review of the literature.Hyperfractionated high-dose rate brachytherapy in the treatment of oral tongue cancer.The changes of tumour vascular endothelial growth factor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma.Radiotherapy-Associated Long-term Modification of Expression of the Inflammatory Biomarker Genes ARG1, BCL2L1, and MYC.Technological advances in radiotherapy for esophageal cancerHighly Efficient Training, Refinement, and Validation of a Knowledge-based Planning Quality-Control System for Radiation Therapy Clinical Trials.Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2).SMARCB1/INI1-deficient sinonasal carcinoma shows methylation of RASSF1 gene: A clinicopathological, immunohistochemical and molecular genetic study of a recently described entity.Carrier molecules and extraction of circulating tumor DNA for next generation sequencing in colorectal cancer.Neoadjuvant chemoradiotherapy of rectal carcinoma : Baseline hematologic parameters influencing outcomes.The presence of high-risk human papillomavirus (HPV) E6/E7 mRNA transcripts in a subset of sinonasal carcinomas is evidence of involvement of HPV in its etiopathogenesis.Cancer in the elderly in the Czech Republic.Non-closure of peritoneum after abdominal hysterectomy for uterine carcinoma does not increase late intestinal radiation morbidityATM and TGFB1 genes polymorphisms in prediction of late complications of chemoradiotherapy in patients with locally advanced cervical cancer.Quantitative evaluation of the benefit of fiducial image-guidance for prostate cancer intensity modulated radiation therapy using daily dose volume histogram analysis.Feasibility of atlas-based active bone marrow sparing intensity modulated radiation therapy for cervical cancer.Epidermal growth factor receptor as a predictor of tumor response to preoperative chemoradiation in locally advanced gastric carcinoma.In Reply to Singh.[Prognostic significance of changes of tumor epidermal growth factor receptor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma].Histopathologic Features are more Important Prognostic Factors than Primary Tumour Location in Gastro-oesophageal Adenocarcinoma Treated with Preoperative Chemoradiation and SurgeryHigh-dose-rate brachytherapy in early oral cancer with close or positive marginsPredicting factors for locoregional failure of high-dose-rate brachytherapy for early-stage oral cancerPerioperative Hyperfractionated High-Dose Rate Brachytherapy for the Treatment of Soft Tissue Sarcomas: Multicentric ExperienceHigh-dose rate brachytherapy in the treatment of penile carcinoma--first experience
P50
Q35768837-82C7A95F-920B-484D-8AF3-FF9A21062E0BQ37392302-BEB25BAE-EB6A-4400-BCAE-95265506B3B7Q37743143-F33DFC0D-22FE-4E26-B2EB-6A1C92128957Q37743903-8C534518-54DD-40E1-8A7C-1E675C45550CQ37812088-D62DDC30-10CE-4C68-95FC-ECE4E007464BQ38383439-F2EA4183-D788-4A61-98B1-645E7EE88FD1Q38996902-03F7A6DC-AE9B-4639-95B1-C43C0AEA4BB3Q39030964-13E724C5-1513-4EC8-9572-416AEAC4FCDFQ39488839-09FC3264-F21E-4085-93D3-330BE8A4AC0DQ39703037-285C4419-5E18-4245-9D09-69A1B75A8679Q41079680-3C7E3803-D073-4EA4-AF8F-37E880B6769EQ41471262-33A9AEE0-6E1B-4961-BCD1-03F6D5EAE0B7Q41966422-5CC7E24B-FFFD-47E1-A6E2-8386E1F6FC94Q44083931-4A8B3539-B29F-444C-933C-C970B3E44F8FQ44206813-4C882E28-3E9E-4B06-A37E-1FBB0C9015FEQ45069655-9A6D109B-2B11-4E7C-8BDF-A6C4EB31CA8BQ46240826-A6EA4DA9-5523-43C3-8CCD-00E0B63ECAD4Q46777906-540C47B9-C0CC-4980-A986-C9B555B8D4DEQ54493763-3469D700-77D3-4164-B956-D2CB9CD0DC13Q59482283-319734B3-E435-4E27-BFA5-AAF5AF7E2D5DQ59482385-845B112D-C3F9-41AF-B07D-63B2C27C0898Q59482556-531E2A05-5F8B-4A01-B6D3-CCF08A99F672Q62977476-35FBF3D1-F032-4AE3-BE91-0CCD3F456E4DQ84721951-7D678F61-3473-456B-8CDF-1505B530ED6C
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Igor Sirak
@ast
Igor Sirak
@en
Igor Sirak
@es
Igor Sirak
@nl
Igor Sirak
@sl
Igor Sirák
@cs
type
label
Igor Sirak
@ast
Igor Sirak
@en
Igor Sirak
@es
Igor Sirak
@nl
Igor Sirak
@sl
Igor Sirák
@cs
prefLabel
Igor Sirak
@ast
Igor Sirak
@en
Igor Sirak
@es
Igor Sirak
@nl
Igor Sirak
@sl
Igor Sirák
@cs
P1053
T-7769-2017
P106
P1153
14070624900
P21
P214
154149841887702841329
P31
P3829
P496
0000-0002-5972-3866
P691
P7859
viaf-154149841887702841329